AUTHOR=Perrone Clara , Pomella Silvia , Cassandri Matteo , Pezzella Michele , Milano Giuseppe Maria , Colletti Marta , Cossetti Cristina , Pericoli Giulia , Di Giannatale Angela , de Billy Emmanuel , Vinci Maria , Petrini Stefania , Marampon Francesco , Quintarelli Concetta , Taulli Riccardo , Roma Josep , Gallego Soledad , Camero Simona , Mariottini Paolo , Cervelli Manuela , Maestro Roberta , Miele Lucio , De Angelis Biagio , Locatelli Franco , Rota Rossella TITLE=MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression JOURNAL=Frontiers in Oncology VOLUME=12 YEAR=2022 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.835642 DOI=10.3389/fonc.2022.835642 ISSN=2234-943X ABSTRACT=
Rhabdomyosarcoma (RMS) is a pediatric myogenic soft tissue sarcoma. The Fusion-Positive (FP) subtype expresses the chimeric protein PAX3-FOXO1 (P3F) while the Fusion-Negative (FN) is devoid of any gene translocation. FP-RMS and metastatic FN-RMS are often unresponsive to conventional therapy. Therefore, novel therapeutic approaches are needed to halt tumor progression. NOTCH signaling has oncogenic functions in RMS and its pharmacologic inhibition through γ-secretase inhibitors blocks tumor growth